Initial multicenter experience using a novel endoscopic tack and suture system for challenging GI defect closure and stent fixation (with video) - 14/01/22
Abstract |
Background and Aims |
Closure of endoscopic resection defects can be achieved with through-the-scope clips, over-the-scope clips, or endoscopic suturing. However, these devices are often limited by their inability to close large, irregular, and difficult-to-reach defects. Thus, we aimed to assess the feasibility and safety of a novel through-the-scope, suture-based closure system developed to overcome these limitations.
Methods |
This was a retrospective multicenter study involving 8 centers in the United States. Primary outcomes were feasibility and safety of early use of the device. Secondary outcomes were assessment of need for additional closure devices, prolonged procedure time, and technical feasibility of performing the procedure with an alternative device(s).
Results |
Ninety-three patients (48.4% women) with mean age 63.6 ± 13.1 years were included. Technical success was achieved in 83 patients (89.2%), and supplemental closure was required in 24.7% of patients (n = 23) with a mean defect size of 41.6 ± 19.4 mm. Closure with an alternative device was determined to be impossible in 24.7% of patients because of location, size, or shape of the defect. The use of the tack and suture device prolonged the procedure in 8.6% of cases but was considered acceptable. Adverse events occurred in 2 patients (2.2%) over a duration of follow-up of 34 days (interquartile range, 13-93.5) and were mild and moderate in severity. No serious adverse events or procedure-related deaths occurred.
Conclusions |
The novel endoscopic through-the-scope tack and suture system is safe, efficient, and permits closure of large and irregularly shaped defects that were not possible with established devices.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Abbreviations : AE, ESD, IQR, OTS, TTS
Plan
| DISCLOSURE: The following authors disclosed financial relationships: L. M. Wong Kee Song: Consultant for Steris Corporation, Olympus, and Intuitive Surgical. S. N. Stavropoulos: Consultant for Olympus, Boston Scientific, Medtronic, and Neptune Medical. N. Fukami: Consultant for Creo Medical, Boston Scientific, and Olympus. N. B. Marya: Consultant for Boston Scientific. C. Marshall: Consultant for Olympus Tokyo. M. A. Khashab: Consultant for Boston Scientific, Olympus, Apollo Endosurgery, Medtronic, and GI Supply. G. B. Haber: Consultant for Boston Scientific, Cook Medical, Erbe, Olympus, Ovesco, and Endogastric Solutions; speaker for Boston Scientific and Olympus; medical advisory board for Covidien/Medtronic, Microtech, and Aries Pharmaceutical; speaker’s bureau for Aries Pharmaceutical. H. Aihara: Consultant for Olympus America, Boston Scientific, Fujifilm Medical Systems, Medtronic, ConMed, Lumendi, and 3D Matrix. V. Chandrasekhara: Consultant for Covidien; advisory board for Interpace Diagnostics; shareholder at Nevakar Corporation. B. K. Abu Dayyeh: Consultant for USGI, Olympus, Boston Scientific, Hemostasis, Dyamx, and Endogastric Solutions; research support from Apollo Endosurgery, USGI, Boston Scientific, and Medtronic; speaker for Olympus, Medtronic, and Johnson & Johnson. A. C. Storm: Consultant for Apollo Endosurgery, GI Dynamics, Olympus, Erbe, Enterasense, and Endo-TAGSS; research support from Apollo Endosurgery and Boston Scientific. All other authors disclosed no financial relationships. |
Vol 95 - N° 2
P. 373-382 - février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
